Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Antengene-Gastric

More Like This

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

GlobeNewswire associated0

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma

PR Newswire associated0

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial